• BioMarin Pharmaceutical Inc., of San Rafael, Calif., missed earnings estimates by 1 cent, posting a fourth-quarter GAAP net loss of $39.8 million, or 31 cents per share. The firm's revenue totaled $127.9 million, falling short of consensus estimates of $131.4 million. Sales of mucopolysaccharidoses enzyme replacement therapy Naglazyme (galsulfase) totaled $69.4 million, while sales of phenylketonuria drug Kuvan (sapropterin dihydrochloride) came in at $37.6 million for the three-month period. Sales of Firdapse (amifampridine) for rare autoimmune disease Lambert-Eaton myasthenic syndrome were $3.6 million. As of March 31, BioMarin had cash, cash equivalents and short- and long-term investments totaling $525.7 million. The company's shares (NASDAQ:BMRN) closed Friday at $63.18 up 31 cents.